Levamlodipine

Levamlodipine (S‑amlodipine) is the pharmacologically active enantiomer of amlodipine, used as a dihydropyridine calcium channel blocker for hypertension and related cardiovascular indications. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019. It is grouped under the following drug class(es): Calcium Channel Blockers and Vasodilating agents. Its therapeutic use is listed as antihypertensives. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include S-Amlodipine and (-)-Amlodipine. Its PubChem CID is 9822750.